Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

648 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Lassen U, Miller WH, Hotte S, Evans TR, Kollmansberger C, Adamson D, Nielsen DL, Spicer J, Chen E, Meyer T, Brown K, Rafi R, Sawyer MB. Lassen U, et al. Among authors: miller wh. Cancer Chemother Pharmacol. 2013 Feb;71(2):543-9. doi: 10.1007/s00280-012-2038-0. Epub 2012 Nov 30. Cancer Chemother Pharmacol. 2013. PMID: 23196640 Clinical Trial.
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Nemunaitis J, Young A, Ejadi S, Miller W, Chen LC, Nichols G, Blotner S, Vazvaei F, Zhi J, Razak A. Nemunaitis J, et al. Cancer Chemother Pharmacol. 2018 Mar;81(3):529-537. doi: 10.1007/s00280-018-3521-z. Epub 2018 Jan 24. Cancer Chemother Pharmacol. 2018. PMID: 29368050
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH Jr, Hansen AR, Lee JS, Tsai F, Solomon BJ, Kim TM, Rolfo C, Giranda V, Ren Y, Liu F, Kandala B, Freshwater T, Wang JS. Armstrong AJ, et al. Among authors: miller wh jr. Invest New Drugs. 2024 May 20. doi: 10.1007/s10637-024-01444-0. Online ahead of print. Invest New Drugs. 2024. PMID: 38767685 No abstract available.
Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.
Huang F, Gonçalves C, Bartish M, Rémy-Sarrazin J, Issa ME, Cordeiro B, Guo Q, Emond A, Attias M, Yang W, Plourde D, Su J, Gimeno MG, Zhan Y, Galán A, Rzymski T, Mazan M, Masiejczyk M, Faber J, Khoury E, Benoit A, Gagnon N, Dankort D, Journe F, Ghanem GE, Krawczyk CM, Saragovi HU, Piccirillo CA, Sonenberg N, Topisirovic I, Rudd CE, Miller WH Jr, Del Rincón SV. Huang F, et al. Among authors: miller wh jr. J Clin Invest. 2024 May 1;134(9):e181575. doi: 10.1172/JCI181575. J Clin Invest. 2024. PMID: 38690739 Free PMC article. No abstract available.
MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
Zhan Y, Guo J, Yang W, Goncalves C, Rzymski T, Dreas A, Żyłkiewicz E, Mikulski M, Brzózka K, Golas A, Kong Y, Ma M, Huang F, Huor B, Guo Q, da Silva SD, Torres J, Cai Y, Topisirovic I, Su J, Bijian K, Alaoui-Jamali MA, Huang S, Journe F, Ghanem GE, Miller WH Jr, Del Rincón SV. Zhan Y, et al. Among authors: miller wh jr. J Clin Invest. 2024 Apr 15;134(8):e181338. doi: 10.1172/JCI181338. J Clin Invest. 2024. PMID: 38618965 Free PMC article. No abstract available.
Correction: MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ.
Guo Q, Li VZ, Nichol JN, Huang F, Yang W, Preston SEJ, Talat Z, Lefrère H, Yu H, Zhang G, Basik M, Gonçalves C, Zhan Y, Plourde D, Su J, Torres J, Marques M, Habyan SA, Bijian K, Amant F, Wichter M, Behbod F, McCaffrey L, Alaoui-Jamali M, Giannakopoulos NV, Brackstone M, Postovit LM, Del Rincón SV, Miller WH Jr. Guo Q, et al. Among authors: miller wh jr. Cancer Res. 2024 Apr 15;84(8):1373. doi: 10.1158/0008-5472.CAN-24-0461. Cancer Res. 2024. PMID: 38616659 No abstract available.
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH Jr, Hansen AR, Lee JS, Tsai F, Solomon BJ, Kim TM, Rolfo C, Giranda V, Ren Y, Liu F, Kandala B, Freshwater T, Wang JS. Armstrong AJ, et al. Among authors: miller wh jr. Invest New Drugs. 2024 Feb;42(1):145-159. doi: 10.1007/s10637-023-01410-2. Epub 2024 Feb 7. Invest New Drugs. 2024. PMID: 38324085 Free PMC article. Clinical Trial.
Tunable PhenoCycler imaging of the murine pre-clinical tumour microenvironments.
Abraham MJ, Goncalves C, McCallum P, Gupta V, Preston SEJ, Huang F, Chou H, Gagnon N, Johnson NA, Miller WH, Mann KK, Del Rincon SV. Abraham MJ, et al. Among authors: miller wh. Cell Biosci. 2024 Feb 4;14(1):19. doi: 10.1186/s13578-024-01199-4. Cell Biosci. 2024. PMID: 38311785 Free PMC article.
Polypathologies and Animal Models of Traumatic Brain Injury.
Freeman-Jones E, Miller WH, Work LM, Fullerton JL. Freeman-Jones E, et al. Among authors: miller wh. Brain Sci. 2023 Dec 12;13(12):1709. doi: 10.3390/brainsci13121709. Brain Sci. 2023. PMID: 38137157 Free PMC article. Review.
648 results